Optimal dosage determination of a hypocholesterolemic bitter yam proprietary preparation in diet-induced hypercholesterolemic mice

Coronary heart disease, a condition associated with dyslipidemias including hyperlipidemia and low HDL-C levels, has been an increasing problem in the developing world. Conventional treatment for hyperlipidemia often present with unfavourable side effects, leading to the need for development of drugs from natural products. The hypoglycemic and hypocholesterolemic properties of the Jamaican bitter yam have previously been demonstrated however consumption at a high dosage presents with various adverse effects. This study is therefore geared towards the determination of an optimal dosage for the consumption of a proprietary preparation made from this yam species. Hypercholesterolemic mice were fed the preparation at various dosages (4, 2, 1, 0.5%) for 3 weeks after which they were phlebotomized then euthanized. Organs were stored at -80°C until required for analysis. The optimal dosage for supplementation, which resulted in significant decreases in serum cholesterol and oxidative stress without eliciting adverse effects, was found to be 2%. The results from this study points to the need for future in-depth studies involving dietary supplementation at the 2% supplementation level.&nbsp

Cellular and molecular activities of IP6 in disease prevention and therapy

IP6 (phytic acid) is a naturally occurring compound in plant seeds and grains. It is a poly-phosphorylated inositol derivative that has been shown to exhibit many biological activities that accrue benefits in health and diseases (cancer, diabetes, renal lithiasis, cardiovascular diseases, etc.). IP6 has been shown to have several cellular and molecular activities associated with its potential role in disease prevention. These activities include anti-oxidant properties, chelation of metal ions, inhibition of inflammation, modulation of cell signaling pathways, and modulation of the activities of enzymes and hormones that are involved in carbohydrate and lipid metabolism. Studies have shown that IP6 has anti-oxidant properties and can scavenge free radicals known to cause cellular damage and contribute to the development of chronic diseases such as cancers and cardiovascular diseases, as well as diabetes mellitus. It has also been shown to possess anti-inflammatory properties that may modulate immune responses geared towards the prevention of inflammatory conditions. Moreover, IP6 exhibits anti-cancer properties through the induction of cell cycle arrest, promoting apoptosis and inhibiting cancer cell growth. Additionally, it has been shown to have anti-mutagenic properties, which reduce the risk of malignancies by preventing DNA damage and mutations. IP6 has also been reported to have a potential role in bone health. It inhibits bone resorption and promotes bone formation, which may help in the prevention of bone diseases such as osteoporosis. Overall, IP6’s cellular and molecular activities make it a promising candidate for disease prevention. As reported in many studies, its anti-inflammatory, anti-oxidant, and anti-cancer properties support its inclusion as a dietary supplement that may protect against the development of chronic diseases. However, further studies are needed to understand the mechanisms of action of this dynamic molecule and its derivatives and determine the optimal doses and appropriate delivery methods for effective therapeutic use.Texas A&M University-Corpus Christi supported the publication of this manuscript

New Frontiers for the Use of IP6 and Inositol Combination in Treating Diabetes Mellitus: A Review

Inositol, or myo-inositol, and associated analog molecules, including myo-inositol hexakisphosphate, are known to possess beneficial biomedical properties and are now being widely studied. The impact of these compounds in improving diabetic indices is significant, especially in light of the high cost of treating diabetes mellitus and associated disorders globally. It is theorized that, within ten years, the global population of people with the disease will reach 578 million individuals, with the cost of care projected to be approximately 2.5 trillion dollars. Natural alternatives to pharmaceuticals are being sought, and this has led to studies involving inositol, and myo-inositol-hexakisphosphate, also referred to as IP6. It has been reported that IP6 can improve diabetic indices and regulate the activities of some metabolic enzymes involved in lipid and carbohydrate metabolism. Current research activities have been focusing on the mechanisms of action of inositol and IP6 in the amelioration of the indices of diabetes mellitus. We demonstrated that an IP6 and inositol combination supplement may regulate insulin secretion, modulate serum leptin concentrations, food intake, and associated weight gain, which may be beneficial in both prediabetic and diabetic states. The supplement attenuates vascular damage by reducing red cell distribution width. Serum HDL is increased while serum triglycerides tend to decrease with consumption of the combination supplement, perhaps due to the modulation of lipogenesis involving reduced serum lipase activity. We also noted increased fecal lipid output following combination supplement consumption. Importantly, liver function was found to be preserved. Concurrently, serum reactive oxygen species production was reduced, indicating that inositol and IP6 supplement consumption may reduce free radical damage to tissues and organs as well as serum lipids and blood glucose by preserving liver function. This review provides an overview of the findings associated with inositol and IP6 supplementation in the effective treatment of diabetes with a view to proposing the potential mechanisms of action

New frontiers for the use of IP6 and inositol combination in treating diabetes mellitus: a Review

Inositol, or myo-inositol, and associated analog molecules, including myo-inositol hexakisphosphate, are known to possess beneficial biomedical properties and are now being widely studied. The impact of these compounds in improving diabetic indices is significant, especially in light of the high cost of treating diabetes mellitus and associated disorders globally. It is theorized that, within ten years, the global population of people with the disease will reach 578 million individuals, with the cost of care projected to be approximately 2.5 trillion dollars. Natural alternatives to pharmaceuticals are being sought, and this has led to studies involving inositol, and myo-inositol-hexakisphosphate, also referred to as IP6. It has been reported that IP6 can improve diabetic indices and regulate the activities of some metabolic enzymes involved in lipid and carbohydrate metabolism. Current research activities have been focusing on the mechanisms of action of inositol and IP6 in the amelioration of the indices of diabetes mellitus. We demonstrated that an IP6 and inositol combination supplement may regulate insulin secretion, modulate serum leptin concentrations, food intake, and associated weight gain, which may be beneficial in both prediabetic and diabetic states. The supplement attenuates vascular damage by reducing red cell distribution width. Serum HDL is increased while serum triglycerides tend to decrease with consumption of the combination supplement, perhaps due to the modulation of lipogenesis involving reduced serum lipase activity. We also noted increased fecal lipid output following combination supplement consumption. Importantly, liver function was found to be preserved. Concurrently, serum reactive oxygen species production was reduced, indicating that inositol and IP6 supplement consumption may reduce free radical damage to tissues and organs as well as serum lipids and blood glucose by preserving liver function. This review provides an overview of the findings associated with inositol and IP6 supplementation in the effective treatment of diabetes with a view to proposing the potential mechanisms of action

Evaluation of the effects of bitter yam tuber supplementation on serum parameters used to assess hepatotoxicity and nephrotoxicity in transgenic mice

The Jamaican bitter yam (Dioscorea polygonoides) (ITIS) is known to possess potent antidiabetic and hypocholesterolemic properties and can therefore be exploited for associated nutraceutical/pharmaceutical purposes. It however possesses bioactive compounds known to promote organ damage when ingested in excess. This study investigates the effects of bitter yam consumption at a concentration of 5% on liver and kidney damage/function parameters. Normocholesterolemic mice fed bitter yam supplemented diets experienced significant increases in serum aspartate aminotransferase activity and bilirubin, magnesium and phosphorus concentrations. Significant increases were also observed in serum aspartate aminotransferase activity and blood urea nitrogen concentration of the genetically modified hypercholesterolemic mice fed supplemented diets. These results suggest mild kidney damage in both mice species and a significant increase in the rate of erythrocyte haemolysis in the normocholesterolemic mice